FDA Approvals
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with Obinutuzumab.
Learn More
On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy.
Learn More
Pfizer Oncology is proud to announce the FDA approval of a new pediatric indication for BESPONSA® (inotuzumab ozogamicin).
Learn More
On March 21, 2024, the Food and Drug Administration approved safety labeling changes for fluorouracil injection products.
Learn More
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]).
Learn More
National Guideline Updates
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Bladder Cancer.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Screening and Diagnosis.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Distress Management.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for Gastric Cancer.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Breast Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer v2.2024
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Head and Neck Cancers to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Head and Neck Cancers v3.2024.
Learn More
ASCO News
View ASCO Daily News Here:
Learn More
Practices, Providers Face Uncertainty Following Change Healthcare Ransomware Attack.
Learn More
Cancer Care Providers Applaud Final Rule to Strengthen Health Insurance Standards.
Learn More
New ASCO Guideline Recommendations Answer Key Questions About Vaccinating Adults with Cancer.
Learn More
Congress to Finalize Cancer Research Funding Levels for FY 2024.
Learn More
2024 Medicare Provider Conversion Factor Updated to Reflect Federal Spending Legislation.
Learn More
New ASCO Policy Statement Calls for Global Equity in Cancer Clinical Trials.
Learn More
CMA News
View California Medical Association Newswire here:
Learn More
Please share your feedback on Change Healthcare cyberattack: Deadline extended to April 3.
Learn More
Reminder: Optum offering temporary funding assistance for providers affected by cyberattack.
Learn More
Biden Administration announces advanced payments for physicians affected by cyberattack.
Learn More
New York Times video on prior authorization spotlights CMA physicians and California patients.
Learn More
CMS reopens MIPS Extreme/Uncontrollable Circumstances exception application due to cyberattack.
Learn More
Final federal spending bills allow half of 3.37% Medicare cut to remain in effect.
Learn More
CMS releases updated fee schedule conversion factor.
Learn More
CMS & Noridian Updates
Billing and Coding: MolDX: Proteomics Testing (A59641) – R2 – Effective January 31, 2024.
Learn More
MolDX: NRAS Genetic Testing (L36335) – R7 – Effective July 27, 2023.
Learn More
Optum, the parent company for Change Healthcare, has worked with Noridian to transition providers enrolled in Change Healthcare connections to the Optum iEDI Clearinghouse.
Learn More
Read MLNC Newsletter here:
Learn More
View CMS Medicare Learning Network (MLN) Matters (MM) New Waived Tests:
Learn More
View CMS Medicare Learning Network (MLN) Matters (MM) Stay of Enrollment:
Learn More
Coding and Reimbursement Updates
View E-Reimbursement Newsletter Here:
Learn More
View Breaking News Optum/Change Outage Update Here:
Learn More
Other
Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer. KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.
Learn More
